|
nasdaq:lumo
|
3905881
|
Apr 21st, 2024 12:00AM
|
Lumos Pharma
|
2.7K
|
44.00
|
Open
|
|
Apr 20th, 2024 11:44PM
|
Apr 20th, 2024 11:44PM
|
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.
Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.
As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
|
Open
|
|
Open
|
4200 Marathon Blvd
|
Austin
|
Texas
|
US
|
78756
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
147095
|
Apr 21st, 2024 12:00AM
|
NewLink Genetics
|
1.9K
|
32.00
|
Open
|
|
Apr 20th, 2024 11:44PM
|
Apr 20th, 2024 11:44PM
|
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
|
Open
|
|
Open
|
2503 S Loop Dr
|
Ames
|
IA
|
US
|
50010
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
3905881
|
Apr 20th, 2024 12:00AM
|
Lumos Pharma
|
2.7K
|
44.00
|
Open
|
|
Apr 19th, 2024 11:41PM
|
Apr 20th, 2024 05:16PM
|
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.
Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.
As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
|
Open
|
|
Open
|
4200 Marathon Blvd
|
Austin
|
Texas
|
US
|
78756
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
147095
|
Apr 20th, 2024 12:00AM
|
NewLink Genetics
|
1.9K
|
32.00
|
Open
|
|
Apr 19th, 2024 11:41PM
|
Apr 20th, 2024 05:16PM
|
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
|
Open
|
|
Open
|
2503 S Loop Dr
|
Ames
|
IA
|
US
|
50010
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
147095
|
Apr 19th, 2024 12:00AM
|
NewLink Genetics
|
1.9K
|
32.00
|
Open
|
|
Apr 18th, 2024 11:48PM
|
Apr 18th, 2024 11:48PM
|
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
|
Open
|
|
Open
|
2503 S Loop Dr
|
Ames
|
IA
|
US
|
50010
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
3905881
|
Apr 19th, 2024 12:00AM
|
Lumos Pharma
|
2.7K
|
44.00
|
Open
|
|
Apr 18th, 2024 11:48PM
|
Apr 18th, 2024 11:48PM
|
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.
Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.
As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
|
Open
|
|
Open
|
4200 Marathon Blvd
|
Austin
|
Texas
|
US
|
78756
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
3905881
|
Apr 18th, 2024 12:00AM
|
Lumos Pharma
|
2.7K
|
44.00
|
Open
|
|
Apr 17th, 2024 11:56PM
|
Apr 18th, 2024 06:36PM
|
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.
Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.
As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
|
Open
|
|
Open
|
4200 Marathon Blvd
|
Austin
|
Texas
|
US
|
78756
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
147095
|
Apr 18th, 2024 12:00AM
|
NewLink Genetics
|
1.9K
|
32.00
|
Open
|
|
Apr 17th, 2024 11:56PM
|
Apr 18th, 2024 06:36PM
|
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
|
Open
|
|
Open
|
2503 S Loop Dr
|
Ames
|
IA
|
US
|
50010
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
3905881
|
Apr 17th, 2024 12:00AM
|
Lumos Pharma
|
2.7K
|
44.00
|
Open
|
|
Apr 16th, 2024 11:38PM
|
Apr 17th, 2024 03:01PM
|
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.
Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.
As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
|
Open
|
|
Open
|
4200 Marathon Blvd
|
Austin
|
Texas
|
US
|
78756
|
|
Lumos Pharma
|
|
|
|
nasdaq:lumo
|
147095
|
Apr 17th, 2024 12:00AM
|
NewLink Genetics
|
1.9K
|
32.00
|
Open
|
|
Apr 16th, 2024 11:38PM
|
Apr 17th, 2024 03:01PM
|
NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.
Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.
|
Open
|
|
Open
|
2503 S Loop Dr
|
Ames
|
IA
|
US
|
50010
|
|
Lumos Pharma
|
|
|